


MEDICINAL PRODUCTS 2019

Myriad genetics

MYRIAD GENETICS INC Rank 2 of 50





MEDICINAL PRODUCTS 2019



MYRIAD GENETICS INC Rank 2 of 50

The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 74% points. The greatest weakness of MYRIAD GENETICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 4.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 144% points above the market average of -5.9%.

| Input Variable | Value in 1000 USD |
|------------------------------------|----------------------|
| Assets, Current | 326,400 |
| Assets, Non-Current | 30,700 |
| General and Administrative Expense | 467,100 |
| Goodwill | 773,800 |
| Liabilities, Current | 102,200 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 1,700 |
| Other Expenses | 102,000 |
| Other Liabilities | 107,000 |
| Other Net Income | -1,800 |
| Other Revenues | 772,600 |
| Property, Plant and Equipment, Net | 43,200 |
| Research and Development | 70,800 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Liabilities | 209,200 |
| Assets | 1,174,100 |
| Expenses | 639,900 |
| Revenues | 772,600 |
| Stockholders Equity | 964,900 |
| Net Income | 130,900 |
| Comprehensive Net Income | 131,750 |
| Economic Capital Ratio | 138% |

